Fig. 2From: Real-life cost-effectiveness of benralizumab in patients with severe asthmaClinical, functional, and laboratory data at baseline and at 3, 6, and 12 months of treatment. a FEV1 mL; b FEV1%; c ACT (asthma control test); d No. of emergency department visits: e No. of oral corticosteroid courses; f Oral prednisone dose (mg/day); g Inhaled budesonide dose (μg/day); h Blood eosinophils (cells/μL). Data expressed as means. *p < 0.001Back to article page